The initiative looks to improve treatments for chronic pain, curb the rates of opioid use disorder (OUD) and overdose, and achieve long-term recovery from opioid addiction.
The National Institute of Health (NIH) awarded $945 million from its 2019 fiscal year funding to 41 states for grants, contracts, and cooperative agreements through the Helping to End Addiction Long-term Initiative (NIH HEAL Initiative). The initiative looks to improve treatments for chronic pain, curb the rates of opioid use disorder (OUD) and overdose, and achieve long-term recovery from opioid addiction, according to a Sept. 26, 2019 press release.
The initiative will gather expertise from several NIH institutes and centers to aid in:
Translation of research to practice for the treatment of opioid addiction
New strategies to prevent and treat opioid addiction
Enhanced outcomes for infants and children exposed to opioids
Novel medication options for opioid use disorder and overdose
Clinical research in pain management
Preclinical and translational research in pain management.
“President Trump’s approach to the opioid crisis and HHS [Health and Human Services’] strategy have both been based in the best science we have,” said HHS Secretary Alex Azar, in the press release. “We have effective tools, such as medication-assisted treatment, but we still need better ways to treat opioid addiction and manage pain in an effective, personalized way. This historic investment by NIH was made possible by funding secured from Congress by President Trump and will support our work in the current crisis and lay the work for a healthier future.”
The initiative also provides scientific solutions for several problems that hinder progress on addressing the crisis including, appropriate OUD treatment, the different types of pain associated with OUD, and understanding the risks of long-term opioid therapy, the press release said.
“It’s clear that a multi-pronged scientific approach is needed to reduce the risks of opioids, accelerate development of effective non-opioid therapies for pain and provide more flexible and effective options for treating addiction to opioids,” said NIH Director Francis S. Collins, MD, PhD, who launched the initiative in early 2018, in the press release. “This unprecedented investment in the NIH HEAL Initiative demonstrates the commitment to reversing this devastating crisis.”
“We need to ensure that people with chronic pain have effective treatment options that don’t expose them to the risk of opioids,” added Rebecca G. Baker, PhD, director, NIH HEAL Initiative, in the press release. “Preventing opioid misuse and addiction through enhanced pain management and improving treatments for OUD and addiction are both critical parts of our trans-NIH response to the opioid crisis.”
Source: NIH
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.